Bedard, P. L., Jhaveri, K. L., Accordino, M. K., Cervantes, P. A., Gambardella, V., Hamilton, E., Italiano, P. A., Kalinsky, P. K., Krop, P. I. E., Oliveira, M., Schmid, P. P., Saura, C., Turner, P. N., Varga, A., Cheeti, S., Dey, A., Hilz, S., Hutchinson, K. E., Jin, Y., … Juric, D. (2025). Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, multicentre, dose-escalation and dose-expansion phase 1/1b study. European Journal of Cancer, 221, 115397. https://doi.org/10.1016/j.ejca.2025.115397